Literature DB >> 22470601

Irinotecan drug eluting beads used as a treatment of advanced intra hepatic cholangiocarcinoma.

Jean Amede Roch1, John Palma-Gutierrez, Marie Georges Lapalus, Carole Paillet, Frank Pilleul.   

Abstract

This report describes a 74-year-old male with unresectable intrahepatic cholangiocarcinoma (ICC). However surgical procedure is the only curative treatment, it often seems to be ineffective because of the aggressive behaviour of the disease. The role of systemic chemotherapy in the ICC is undefined with a median survival between 6.43 to 12.17 months obtained by using the combination chemotherapy of gemcitabine with cisplatin. In the present case, we performed a targeted treatment using drug eluting beads (DEB) with irinotecan (IRI) administered as transarterial-chemoembolization (TACE). After one session, the tumour vascularity decreased significantly at the one month evaluation on computed tomography (CT) scan of the liver. This case report suggested that minimally invasive transcatheter DEB embolization could be a promising, safe and effective treatment for selective patients with unresectable ICC.

Entities:  

Year:  2008        PMID: 22470601      PMCID: PMC3303241          DOI: 10.3941/jrcr.v2i4.48

Source DB:  PubMed          Journal:  J Radiol Case Rep        ISSN: 1943-0922


  14 in total

1.  Chemoembolization of hepatocellular carcinoma with drug eluting beads.

Authors:  Paolo Del Poggio; Alessandro Maddeo; Giampietro Zabbialini; Antonio Pitì
Journal:  J Hepatol       Date:  2007-04-19       Impact factor: 25.083

2.  Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial.

Authors:  Jennifer J Knox; David Hedley; Amit Oza; Ron Feld; Lillian L Siu; Eric Chen; Mahsan Nematollahi; Gregory R Pond; Jessica Zhang; Malcolm J Moore
Journal:  J Clin Oncol       Date:  2005-04-01       Impact factor: 44.544

3.  Irinotecan drug eluting beads for use in chemoembolization: in vitro and in vivo evaluation of drug release properties.

Authors:  Rachel R Taylor; Yiqing Tang; M Victoria Gonzalez; Peter W Stratford; Andrew L Lewis
Journal:  Eur J Pharm Sci       Date:  2006-09-15       Impact factor: 4.384

Review 4.  Cholangiocarcinoma.

Authors:  C J Yeo; H A Pitt; J L Cameron
Journal:  Surg Clin North Am       Date:  1990-12       Impact factor: 2.741

5.  Combination chemotherapy with gemcitabine and cisplatin as first-line treatment for immunohistochemically proven cholangiocarcinoma.

Authors:  Gyeong-Won Lee; Jung Hun Kang; Hun-Gu Kim; Jong-Sil Lee; Jong-Seok Lee; Joung-Soon Jang
Journal:  Am J Clin Oncol       Date:  2006-04       Impact factor: 2.339

6.  Trans-arterial chemoembolization (TACE) of liver metastases from colorectal cancer using irinotecan-eluting beads: preliminary results.

Authors:  C Aliberti; M Tilli; G Benea; G Fiorentini
Journal:  Anticancer Res       Date:  2006 Sep-Oct       Impact factor: 2.480

7.  Cholangiocarcinoma: advocate an aggressive operative approach with adjuvant chemotherapy.

Authors:  S T Kelley; M Bloomston; F Serafini; L C Carey; R C Karl; E Zervos; S Goldin; P Rosemurgy; A S Rosemurgy
Journal:  Am Surg       Date:  2004-09       Impact factor: 0.688

8.  Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors.

Authors:  A Nakeeb; H A Pitt; T A Sohn; J Coleman; R A Abrams; S Piantadosi; R H Hruban; K D Lillemoe; C J Yeo; J L Cameron
Journal:  Ann Surg       Date:  1996-10       Impact factor: 12.969

9.  Irinotecan with 5-FU/FA in advanced biliary tract adenocarcinomas: a multicenter phase II trial.

Authors:  Jürgen Feisthammel; Konrad Schoppmeyer; Joachim Mössner; Manfred Schulze; Karel Caca; Marcus Wiedmann
Journal:  Am J Clin Oncol       Date:  2007-06       Impact factor: 2.339

Review 10.  Management of cancer of the bile duct.

Authors:  R L Rossi; F W Heiss; C F Beckmann; J W Braasch
Journal:  Surg Clin North Am       Date:  1985-02       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.